How many drugs treat Superficial Ocular Infection?

Drug Landscape tracks 10 marketed treatments for Superficial Ocular Infection (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/superficial-ocular-infection.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Superficial Ocular Infection — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Superficial Ocular Infection (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Superficial Ocular Infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zestril	lisinopril	Generic (originally Merck/AstraZeneca)	Thiazide Diuretic [EPC]	Angiotensin-converting enzyme, Angiotensin-converting enzyme	1987-12-29
Gramoderm	GRAMICIDIN	Pfizer	gramicidin	Thromboxane-A synthase	1968-01-01
Benzamycin	Erythromycin Lactobionate	Pfizer	Macrolide	Potassium voltage-gated channel subfamily H member 2	1964-01-01
Cortisporin	NEOMYCIN	Pfizer	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 1	1957-01-01
Cortisporin	POLYMYXIN B	Pfizer	Polymyxin-class Antibacterial		1957-01-01
Prelone	prednisolone	Generic (originally Schering)	Glucocorticoid (corticosteroid)	Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1	1955-01-01
Cortef	hydrocortisone	Generic (originally Merck/Upjohn)	Corticosteroid [EPC]	Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible	1952-01-01
E-Mycin	erythromycin	Generic (originally Abbott/Lilly)	Macrolide [EPC]	Aldehyde oxidase, Bile salt export pump, Cytochrome P450 1B1	1952-01-01
Chlorocidin	CHLORAMPHENICOL	Parkedale	Amphenicol-class Antibacterial	Cytochrome P450 3A4	1950-01-01
Cortisporin	BACITRACIN	Pfizer	bacitracin	Tyrosine-protein kinase Lck	1948-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 5 drugs in Superficial Ocular Infection
· 2 drugs in Superficial Ocular Infection
Generic (originally Merck/AstraZeneca) · 1 drug in Superficial Ocular Infection
Generic (originally Merck/Upjohn) · 1 drug in Superficial Ocular Infection
Generic (originally Schering) · 1 drug in Superficial Ocular Infection
Hannover Medical School · 1 drug in Superficial Ocular Infection
Merck & Co. · 1 drug in Superficial Ocular Infection
Parkedale · 1 drug in Superficial Ocular Infection
University of Zurich · 1 drug in Superficial Ocular Infection
Generic (originally Abbott/Lilly) · 1 drug in Superficial Ocular Infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Superficial Ocular Infection:

Cite this brief

Drug Landscape (2026). Superficial Ocular Infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/superficial-ocular-infection. Accessed 2026-06-10.

Superficial Ocular Infection full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing